Biomarker discovery for personalized therapy selection in inflammatory bowel diseases: Challenges and promises

• Main Authors: Dahham Alsoud (Author), Séverine Vermeire (Author), Bram Verstockt (Author)
• Format: Book
• Published: Elsevier, 2022-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.
• Notes: 2590-2571; 10.1016/j.crphar.2022.100089
• Keywords: Biomarker discovery; Personalized medicine; Precision; Therapeutic ceiling; IBD; Omics; Therapeutics. Pharmacology; RM1-950
• Source: Current Research in Pharmacology and Drug Discovery, Vol 3, Iss , Pp 100089- (2022)

The past decades witnessed a significant stride in deciphering the pathophysiology of inflammatory bowel disease, which further advanced drug development adding several new biologicals and small molecules to the arsenal of available therapies. Surprisingly, this wealth in therapeutic options did not yield the aspired high durable response rates. In addition, the increase in therapeutic availabilities ignited an increase in research toward biomarkers that could help assign therapies to patients with the highest probability of response. Luckily, major steps have been undertaken in this domain which resulted in the discovery of some interesting biomarkers that are still under validation. However, the pace in which this domain is progressing, the discordance between short-term endpoints in biomarker discovery studies and the ambition of the disease community in modifying disease course, and the uncertainties about the validity of discovered biomarkers highlight the need for a critical appraisal of research conduct in this domain. In this review, we shed light on areas of improvement in biomarker discovery studies that will help optimize the use of available therapies and break the current therapeutic ceiling.